<DOC>
	<DOCNO>NCT01457547</DOCNO>
	<brief_summary>The study compare immunogenicity reactogenicity INFANRIX™ HEXA HEXAVAC™ vaccines 3 , 5 11 - 12 month vaccination schedule .</brief_summary>
	<brief_title>Comparison Immunogenicity Reactogenicity INFANRIX™ HEXA HEXAVAC™ Vaccines Primary Vaccination Course</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Pentetic Acid</mesh_term>
	<mesh_term>Edetic Acid</mesh_term>
	<criteria>A healthy male female subject 8 15 week age time first vaccination . Written inform consent obtain parent guardian subject prior study entry . Free obvious health problem establish medical history clinical examination enter study . Born normal gestation period 36 42 week . Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration study vaccine , plan use study period . Evidence previous intercurrent diphtheria , tetanus , pertussis , polio , hepatitis B and/or Hib vaccination disease . Planned administration vaccine foreseen study protocol since birth period start 30 day administration first dose end 30 day last dose threedose primary vaccination course , exception license Neisseria meningitides conjugate vaccine Bacillus CalmetteGuérin ( BCG ) vaccine give study visit third visit , provide give preferably 4 week interval less 3 week apart study vaccine dos . Chronic administration plan administration immunosuppressant immunemodifying drug since birth . Planned administration immunoglobulins and/or blood product since birth plan administration period 30 day third dose primary vaccination course . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History seizure , progressive neurological disease intracerebral haemorrhage . Major congenital defect serious chronic illness . Acute febrile illness time plan vaccination History allergic disease reaction likely exacerbate component study vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>15 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HEXAVACTM</keyword>
	<keyword>InfanrixTM HEXA</keyword>
	<keyword>DTPa-HBV-IPV-Hib</keyword>
	<keyword>DTPa-HBV-IPV/Hib</keyword>
</DOC>